With increased regulatory scrutiny, pricing and cost pressures, as well as the rapid developments in genomic technology leading to a more personalised approach to medicine and healthcare, businesses and organisations in the life sciences and healthcare sector face a growing number of complex legal and regulatory challenges in order to stay competitive.
Our International Life Sciences & Healthcare group works with over 50% of the world’s largest pharmaceutical, biotechnology and medical devices companies. We have the largest patent litigation group in Europe and are recognised by major global directories as a top tier life sciences firm.
Our focus on business being changed by technology and the digital world enables us to support our clients operating in this rapidly changing environment. Our multidisciplinary team of 240 specialist life sciences and healthcare lawyers worldwide can advise you on every aspect of the business cycle of a life science and healthcare product or service, from incorporation through development to protection and exploitation of intellectual property.
We can advise you on:
If you would like to know more about how we can help your business, please contact Heads of Group: Marc Martens in Brussels and Mark Hilton in London.
Legal 500, 2020
Chambers UK, 2020
Chambers Asia-Pacific, 2020
Chambers Europe, 2019
On 11 September 2020, the National Medical Products Administration ("NMPA") and the China National Intellectual Property Administration ("CNIPA") issued the draft "Implementing Measures for Drug Patent Dispute Early ...
The Australian Government is currently inviting consumers and industry participants to provide feedback on key provisions of the proposed Information Standard for manufacturers of complementary medicines.
As the development of vaccines against COVID-19 is progressing, the question becomes urgent who will be liable if a vaccine is marketed and will cause unexpected adverse effects as a result of the requested speed and ...
Bird & Bird has appointed Mikael Bock as Senior Counsel, strengthening its commercial offering in Sweden.
Bird & Bird has launched a new profile on LinkedIn, focused on presenting their insights on the Nordic market and telling the international law firm's 'Nordic story'.
Our Equity Capital Markets Team has completed a number of deals this Quarter, across a wide variety of sectors.
There are no forthcoming events for this area. Please click on the button below to view past events.
Our latest BioTalk article is now live: Post-Transition Brexit: New MHRA Guidelines on Medical Devices… https://t.co/FxOmxQ5pas
RT @twobirdsIP: New article from Alison Wong 'NMPA and CNIPA issue Draft Patent Linkage Measures in China' https://t.co/oD9BThQ9Fu #patentl…
RT @twobirdsIP: Hot of the Press: @ICLG_GLG Patent Guide 2021 out. Read our contributions here: https://t.co/EpnmjB4HTe #ICLG #Patentlaw #…